This segment focuses on the research, development, and clinical trials of the RaniPill capsule technology for oral delivery of biologics. The core technology involves the RaniPill, a capsule designed to release the drug in the small intestine, where it is absorbed into the bloodstream. Research and development activities include formulation development, preclinical studies, and clinical trials for various therapeutic areas. The segment aims to replace subcutaneous and intravenous injections with oral dosing, improving patient convenience and adherence. This segment covers therapeutic areas such as neuroendocrine tumors, acromegaly, psoriatic arthritis, osteoporosis, growth hormone deficiency, hypoparathyroidism, and type 2 diabetes. The market positioning is based on the potential to disrupt the biologics market by offering a more patient-friendly administration method. Competitive advantages include the proprietary RaniPill technology and the potential for improved patient outcomes and reduced healthcare costs. Future opportunities include expanding the pipeline to include additional biologics and partnering with pharmaceutical companies. Regulatory and clinical aspects involve obtaining FDA approval for each drug-device combination. Partnerships and collaborations are crucial for clinical development and commercialization.

This segment encompasses the development of specific therapeutic programs utilizing the RaniPill platform. It includes research and development activities focused on various drug candidates, such as RT-101 (octreotide), RT-105 (anti-TNF-alpha antibody), RT-102 (parathyroid hormone), RT-109 (human growth hormone), RT-110 (parathyroid hormone), RT-103 (glucagon-like peptide-1 mimetic), and RT-106 (basal insulin). The segment utilizes the RaniPill technology to deliver these drugs orally, targeting specific diseases and conditions. Research includes preclinical studies, clinical trials, and formulation development. The therapeutic areas covered include neuroendocrine tumors, acromegaly, psoriatic arthritis, osteoporosis, growth hormone deficiency, hypoparathyroidism, and type 2 diabetes. The patient impact is significant, as oral administration can improve patient compliance and quality of life. Market positioning involves targeting large and growing markets for these therapeutic areas. Competitive advantages include the potential for improved patient outcomes and reduced healthcare costs. Future opportunities include expanding the pipeline to include additional biologics and partnering with pharmaceutical companies. Regulatory and clinical aspects involve obtaining FDA approval for each drug-device combination. Partnerships and collaborations are crucial for clinical development and commercialization.